Liu Ye 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jan 16, 2024
Insider Transaction Report
Form 4
Liu Ye
Director
Transactions
- Sale
Common Stock, $0.001 par value
2024-01-11$19.45/sh−1,910,500$37,159,225→ 100,221 total(indirect: Ocumension Therapeutics)
Footnotes (1)
- [F1]The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.